Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2545 | Nicotine patch Wiki | 1.00 |
| drug2983 | Placebo patch Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This research is planned to illustrate the efficacy of Therapeutic Plasma Exchange (TPE) treatment in COVID-19 patients with resistant cytokine storm state.
Description: Number of patients deaths of the total of patients included
Measure: mortality Time: 28 dayDescription: to calculate the mean time with oxygen therapy
Measure: the mean time with oxygen therapy Time: through study completion, and average of 1 monthDescription: to calculate the mean time with Non-invasive mechanical ventilation
Measure: the mean time with Non-invasive mechanical ventilation Time: through study completion, and average of 1 monthDescription: to calculate the mean time of intubation
Measure: the mean time of intubation Time: through study completion, and average of 1 monthDescription: To calculate the mean of PaO2/FiO2
Measure: respiratory function parameters Time: through study completion, and average of 1 monthDescription: To calculate the mean of levels of oxygen saturation
Measure: respiratory function parameters Time: through study completion, and average of 1 monthDescription: to evaluate the lung extension of pneumonia
Measure: radiological lung extension Time: through study completion, and average of 1 monthDescription: Days of hospitalization in survivors and/or days at ICU throughout the study
Measure: mean duration of hospitalization and ICU use Time: through study completion, and average of 1 monthDescription: Percentage of patients with dialysis
Measure: the requirement of additional organ support Time: through study completion, and average of 1 monthDescription: To evaluate the effect of TPE on the serum levels of inflammatory markers
Measure: the levels of IL-6 Time: through study completion, and average of 1 monthDescription: To calculate the number of adverse events in patients with COVID-19 treated with TPE
Measure: Incidence of adverse events Time: through study completion, and average of 1 monthDescription: To evaluate the time to RT-PCR virus negativity
Measure: time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity Time: through study completion, and average of 1 monthDescription: To evaluate the effect of TPE on the serum levels of inflammatory markers
Measure: the levels of CRP Time: through study completion, and average of 1 monthDescription: To evaluate the effect of TPE on the serum levels of inflammatory markers
Measure: the levels of procalcitonin (PCT) Time: through study completion, and average of 1 monthDescription: To evaluate the effect of TPE on the serum levels of inflammatory markers
Measure: levels of D-dimer Time: through study completion, and average of 1 monthDescription: To evaluate the effect of TPE on the serum levels of inflammatory markers
Measure: levels of ferritin Time: through study completion, and average of 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports